Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

EMERGENT BIOSOLUTIONS INC.

(EBS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Emergent BioSolutions : Emergency BioSolutions Doses First Patient in Phase 3 Trial of Vaccine Candidate for Chikungunya Virus

10/15/2021 | 07:11am EST


ę MT Newswires 2021
All news about EMERGENT BIOSOLUTIONS INC.
12/02Special Report-U.S. rushed contracts to COVID-19 suppliers with troubled plants
RE
11/30EMERGENT BIOSOLUTIONS INC.(NYSE : EBS) added to S&P 600
CI
11/30EMERGENT BIOSOLUTIONS INC.(NYSE : EBS) added to S&P 600 Health Care
CI
11/30EMERGENT BIOSOLUTIONS INC.(NYSE : EBS) dropped from S&P 400
CI
11/30EMERGENT BIOSOLUTIONS INC.(NYSE : EBS) dropped from S&P 400 Health Care
CI
11/30EMERGENT BIOSOLUTIONS INC.(NYSE : EBS) dropped from S&P 400 - Biotechnology
CI
11/24Janssen COVID-19 vaccine plant in Baltimore gets Health Canada OK
AQ
11/24Canada clears import of J&J COVID-19 vaccine doses made at Emergent plant
RE
11/23Thinking about buying stock in Aptevo Therapeutics, Navitas Semiconductor, Berkshire Gr..
PR
11/22SiTime to Join S&P MidCap 400, Pushing Emergent BioSolutions to S&P SmallCap 600 From N..
MT
More news
Analyst Recommendations on EMERGENT BIOSOLUTIONS INC.
More recommendations
Financials (USD)
Sales 2021 1 689 M - -
Net income 2021 230 M - -
Net Debt 2021 371 M - -
P/E ratio 2021 9,69x
Yield 2021 -
Capitalization 2 222 M 2 222 M -
EV / Sales 2021 1,54x
EV / Sales 2022 1,36x
Nbr of Employees 2 200
Free-Float 88,6%
Chart EMERGENT BIOSOLUTIONS INC.
Duration : Period :
Emergent BioSolutions Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EMERGENT BIOSOLUTIONS INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 41,31 $
Average target price 57,40 $
Spread / Average Target 38,9%
EPS Revisions
Managers and Directors
Robert G. Kramer President, Chief Executive Officer & Director
Richard Scott Lindahl Chief Financial Officer, Treasurer & Executive VP
Fuad El Hibri Executive Chairman
Sharon M. Solomon Chief Information Officer & Senior Vice President
Christopher H. Cabell Head-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
EMERGENT BIOSOLUTIONS INC.-52.90%2 270
JOHNSON & JOHNSON3.80%430 061
ROCHE HOLDING AG19.17%324 115
PFIZER, INC.39.85%290 297
NOVO NORDISK A/S70.26%250 392
ELI LILLY AND COMPANY45.17%222 215